Valuation

GILDGilead Sciences

StockNasdaqUnited StatesHealth careEU retail investors: available

−1.7% today · +40.6% over a year

5/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 70% of the instruments we score

Stability: among the best of its peers. Dividend yield 1.94%.

Gilead Sciences (GILD) valuation against sector peers: P/B 15.9, free-cash-flow yield 6.6%, P/S 6.7.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricGILDSector medianvs median
P/E—30.1 · n=150—
P/B15.93.9 · n=304305% above
P/S6.74.2 · n=29758% above
EV/EBIT—25.8 · n=140—
Free-cash-flow yield6.6%1.4% · n=289359% above
Dividend yield1.94%0.00% · n=361—
Return on equity−22.3%−3.7% · n=306—
Return on invested capital−6.6%0.5% · n=2761,337% below
Gross margin79.9%62.4% · n=20428% above
Net debt / EBITDA—1.30 · n=145—

Value factor: 55 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

LLYEli Lilly & Co48.132.9—1.5%0.6%7/10
JNJJohnson & Johnson39.87.9—3.2%2.0%8/10
ABBVAbbVie49.1—27.13.7%3.0%6/10
UNHUnitedHealth22.83.517.36.3%2.2%10/10
MRKMerck112.58.5—4.5%2.4%9/10
TMOThermo Fisher Scientific36.64.734.72.9%0.3%9/10
AMGNAmgen28.521.325.64.1%2.2%7/10
ABTAbbott30.23.728.33.9%2.8%6/10
PFEPfizer42.41.9—6.9%7.2%1/10
DHRDanaher37.43.035.03.5%0.7%7/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 30 Oct 2026